Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 13/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852106 | 0.88 | ADORA3 (0.42) | USP1ADORA3 | |
| SCHEMBL3848463 | 0.86 | DDR1 (0.38) | USP1DDR1 | |
| SCHEMBL3850531 | 0.79 | KDM1A (0.43) | USP1HSP90AA1HSP90B1TRAP1JAK2 | |
| SCHEMBL3850532 | 0.79 | KDM1A (0.43) | USP1HSP90AA1HSP90B1TRAP1JAK2 | |
| SCHEMBL3845187 | 0.79 | ADORA3 (0.37) | USP1ADORA3JAK2JAK3 | |
| SCHEMBL3846520 | 0.78 | DDR1 (0.43) | USP1HSP90AA1HSP90B1TRAP1ADORA3 | |
| SCHEMBL3846522 | 0.78 | DDR1 (0.43) | USP1HSP90AA1HSP90B1TRAP1ADORA3 | |
| SCHEMBL3845141 | 0.78 | USP1 (0.40) | USP1ADORA3 | |
| SCHEMBL3849028 | 0.77 | DDR1 (0.39) | USP1HSP90AA1HSP90B1TRAP1ADORA3 | |
| SCHEMBL3849031 | 0.77 | DDR1 (0.39) | USP1HSP90AA1HSP90B1TRAP1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | USP1 3253/4885HSP90AA1 3427/4885HSP90B1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.